Immunogenetic surveillance of HIV/AIDS

Infection, Genetics and Evolution

Volumn 12, Issue 7, 2012, Pages 1481-1491

  Stephens, Henry A F ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Class I; GWAS; HIV AIDS; HLA; KIR; Vaccines

Indexed keywords

HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ALLELE; CLADISTICS; CONVERGENT EVOLUTION; DNA POLYMORPHISM; ETHNIC GROUP; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE POOL; GENETIC ASSOCIATION; GENETIC VARIABILITY; GEOGRAPHY; HAPLOTYPE; HLA CLASS 1 GENE; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENETICS; INFECTION CONTROL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR TYPING; NK RECEPTOR GENE; PANDEMIC; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIREMIA;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; EVOLUTION, MOLECULAR; GENES, MHC CLASS I; GENOME-WIDE ASSOCIATION STUDY; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGENETIC PHENOMENA; PANDEMICS; RECEPTORS, IMMUNOLOGIC;

EID: 84865402031     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2012.04.011     Document Type: Review

References (128)

1. Alter G., Martin M.P., Teigen N., Carr W.H., Suscovich T.J., Schneidewind A., Streeck H., Waring M., Meier A., Brander C., Lifson J.D., Allen T.M., Carrington M., Altfeld M. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 2007, 204:3027-3036.
2. Alter G., Rihn S., Streeck H., Teigen N., Piechocka-Trocha A., Moss K., Cohen K., Meier A., Pereyra F., Walker B., Altfeld M. Ligand-independent exhaustion of killer immunoglobulin-like receptor-positive CD8+ T cells in human immunodeficiency virus type 1 infection. J. Virol. 2008, 82:9668-9677.
3. Alter G., Rihn S., Walte K., Nolting A., Martin M., Rosenberg E.S., Miller J.S., Carrington M., Altfeld M. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:6798-6805.
4. Alter G., Kavanagh D., Rihn S., Luteijn R., Brooks D., Oldstone M., van Lunzen J., Altfeld M. IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection. J. Clin. Invest. 2010, 120:1905-1913.
5. Alter G., Heckerman D., Schneidewind A., Fadda L., Kadie C.M., Carlson J.M., Oniangue-Ndza C., Martin M., Li B., Khakoo S.I., Carrington M., Allen T.M., Altfeld M. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 2011, 476:96-100.
6. Bentley G., Higuchi R., Hoglund B., Goodridge D., Sayer D., Trachtenberg E.A., Erlich H.A. High-resolution, high-throughput HLA genotyping by next-generation sequencing. Tissue Antigens 2009, 74:393-403.
7. Beyrer C., Stephens H.A.F. Transmission of HIV/AIDS and other infections in Southeast Asia: cultural and genetic factors. AIDS in Asia 2004, 317-333. Kluwer Academic/Plenum Publishers, New York, USA. M. Essex, Y. Lu (Eds.).
8. Beyrer C., Artenstein A.W., Rungpao S., Stephens H.A.F., VanCott T.C., Robb M.L., Rinkaew M., Birx D.L., Khamboonruang C., Zimmerman P.A., Nelson K.E., Natpratan C. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in Northern Thailand. J. Infect. Dis. 1999, 179:59-67.
9. Bhattacharya T., Daniels M., Heckerman D., Foley B., Frahm N., Kadie C., Carlson J., Yusim K., McMahon B., Gaschen B., Mallal S., Mullins J.I., Nickle D.C., Herbeck J., Rousseau C., Learn G.H., Miura T., Brander C., Walke r B., Korber B. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007, 315:1583-1586.
10. Bjorkman P.J., Sapper M.A., Samraoui B., Bennett W.S., Strominger J.L., Wiley D.C. Structure of the human class I histocompatibility antigen HLA-A2. Nature 1987, 329. 526-512.
11. Bjorkman P.J., Sapper M.A., Samraoui B., Bennett W.S., Strominger J.L., Wiley D.C. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987, 329:512-518.
12. Bond K.B., Sriwanthana B., Hodge T.W., De Groot A.S., Mastro T.D., Young N.L., Promadej N., Altman J.D., Limpakarnjanarat K., McNicholl J.M. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. AIDS Res. Hum. Retroviruses 2001, 17:703-717.
13. Brettle R.P., McNeil A.J., Burns S., Gore S.M., Bird A.G., Yap P.L., MacCallum L., Leen C.S., Richardson A.M. Progression of HIV: follow up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-1985. AIDS 1996, 10:419-430.
14. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., McElrath M.J., Casimiro D.R., Gottesdiener K.M., Chodakewitz J.A., Corey L., Robertson M.N. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893. Step Study Protocol Team.
15. Bunce M., Young N.T., Welsh K.I. Molecular HLA typing-the brave new world. Transplantation 1997, 64:1505-1513.
16. Burton D.R., Desrosiers R.C., Doms R.W., Feinberg M.B., Gallo R.C., Hahn B., Hoxie J.A., Hunter E., Korber B., Landay A., Lederman M.M., Lieberman J., McCune J.M., Moore J.P., Nathanson N., Picker L., Richman D., Rinaldo C., Stevenson M., Watkins D.I., Wolinsky S.M., Zack J.A. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004, 303:316.
17. Cao K., Moormann A.M., Lyke K.E., Masaberg C., Sumba C., Doumbo O.K., Koech D., Lancaster A., Nelson M., Meyer D., Single R., Hartzman R.J., Plowe C.V., Kazura J., Mann D.L., Sztein M.B., Thomson G., Fernandez-Vina M.A. Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens 2004, 63:293-325.
18. Cardon L.R., Bell J.I. Association study designs for complex diseases. Nat. Rev. Genet. 2001, 2:91-99.
19. Carr W.H., Pando M.J., Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J. Immunol. 2005, 175:5222-5229.
20. Carrington M., Nelson G.W., Martin M.P., Kissner T., Vlahov D., Goedert J.J., Kaslow R., Buchbinder S., Hoots K., O'Brien S.J. HLA and HIV-1: heterozgote advantage and B35-Cw04 disadvantage. Science 1999, 283:1748-1752.
21. Chandanayingyong D., Stephens H.A.F., Klaythong R., Sirkong M., Udee S., Longta P., Chantangpol R., Bejrachandra S., Runruang E. HLA-A, -B, -DRB1, -DQA1 and DQB1 polymorphism in Thais. Hum. Immunol. 1997, 53(174-182):1997.
22. Collins K.L., Chen B.K., Kalams S.A., Walker B.D., Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998, 391:397-401.
23. Crum K.A., Logue S.E., Curran M.D., Middleton D. Development of a PCR-SSOP approach capable of defining the natural killer cell inhibitory receptor (KIR) gene sequence repertoires. Tissue Antigens 2000, 56:313-326.
24. Dalmasso C., Carpentier W., Meyer L., Rouzioux C., Goujard C., Chaix M.-L., Lambotte O., Aventtand-Fenoel V., Le Clerc S., Denis de Senneville L., Deveau C., Boufassa F., Debre P., Delfraissy J.-F., Broet P., Theodorou I. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS ONE 2008, 3(12):e3907.
25. Dolin R. HIV vaccine trial results - an opening for further research. N. Engl. J. Med. 2009, 361:2279-2280.
26. Dorak M.T., Tang J., Tang S., Penman-Aguilar A., Cuitinho R.A., Goedaert J.J., Detels R., Kaslow R.A. Influence of human leukocyte antigen-B22 alleles on the course of human immunodeficiency virus type 1 infection in 3 cohorts of white men. J. Infect. Dis. 2003, 188:856-863.
27. Dorak M.T., Tang J., Penman-Aguilar A., Westfall A.O., Zulu I., Lobashevsky E.S., Schaen M.M., Allen S., Kaslow R.A. Transmission of HIV-1 and HLA-B allele-sharing within discordant heterosexual Zambian couples. Lancet 2004, 303:2137-2139.
28. Farquhar C., Rowland-Jones S., Mbori-Ngacha D., Redman M., Lohman B., Slyker J., Otieno P., Obimo E., Rostron T., Ochieng J., Oyungi J., Bosire R., John-Stewart G. Human leukocyte antigen (HLA) B18 and protection against mother-to-child HIV type 1 transmission. AIDS Res. Hum. Retroviruses 2004, 20:692-697.
29. Fellay J., Shianna K.V., Ge D., Colombo S., Ledergerber B., Weale M., Zhang K., Gumbs C., Castanga A., Cossarizza A., Cozzi-Lepri A., De Luca A., Easterbrook P., Francioli P., Mallal S., Martinez-Picado J., Miro J.M., Obel N., Smith J.P., Wyniger J., Descombes P., Antonarakis S.E., Letvin N.L., McMichael A.J., Haynes B.F., Telenti A., Goldstein D.B. A whole genome association study of major determinants for host control of HIV-1. Science 2007, 317:944-947.
30. Fellay J., Ge D., Shianna, Colombo S., Ledergerber B., Cirulli E.T., Urban T.J., Zhang K., Gumbs C., Smith J.P., Castanga A., Cozzi-Lepri A., Luca A., Easterbrook P., Gunthard H.F., Mallal S., Mussini C., Dalmau J., Martinez-Picado J., Miro J.M., Obel N., Wolinsky S.M., Martinson J.J., Detels R., Margolick J.B., Jacobson L.P., Descombes P., Antonarakis S.E., Beckman J.S., O'Brien S.J., Letvin N.L., McMichael A.J., Haynes B.F., Carrington M., Feng S., Telenti A., Goldstein D.B. Common genetic variation and control of HIV-1 in humans. PLoS Genet. 2009, 5(12):e1000791.
31. Fellay J., Frahm N., Shianna K.V., Cirulli E.T., Casimiro D.R., Robertson M.N., Haynes B.F., Geraghty D.E., McElrath M.J., Goldstein D.B. Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. J. Infect. Dis. 2011, 203:773-779. National Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine Immunology; NIAID HIV Vaccine Trials Network.
32. Fitzgerald D.W., Janes H., Robertson M., Coombs R., Frank I., Gilbert P., Loufty M., Mehrotra D., Duerr A. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J. Infect. Dis. 2011, 203:765-772. Step Study Protocol Team.
33. Flores-Villanueva P.O., Hendel H., Caillat-Zucman S., Rappaport J., Burgos-Tiburcio A., Bertin-Maghit S., Ruiz-Morales J.A., Teran M.E., Rodriguez-Tarfur J., Zagury J.-F. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J. Immunol. 2003, 170:1925-1929.
34. Flower D.R. Towards in silico prediction of immunogenic epitopes. Trends Immunol. 2003, 24:667-674.
35. Frahm N., Adams S., Kiepiela P., Linde C.H., Hewitt H.S., Lichterfeld M., Sango K., Brown N.V., Pae E., Wurcel A.G., Altfeld M., Feeney M.E., Allen T.M., Roach T., St John M.A., Daar E.S., Rosenberg E., Korber B., Marincola F., Walker B.D., Goulder P.J., Brander C. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J. Virol. 2005, 79:10218-10225.
36. Frahm N., Kiepiela P., Adams S., Linde C.H., Hewitt H.S., Sango K., Feeney M.E., Addo M.M., Lichterfeld M., Lahaie M.P., Pae E., Wurcel A.G., Roach T., St John M.A., Altfield M., Marincola F.M., Moore C., Mallal S., Carrington M., Heckerman D., Allen T., Mullins J., Korber B., Goulder P.J.R., Walker B.D., Brander C. Control of human immunodeficiency virus by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 2006, 7:173-189.
37. Gabriel C., Danzer M., Hackl C., Kopal G., Hufnagl P., Hofer K., Polin H., Stabentheiner S., Pröll J. Rapid high-throughput human leukocyte antigen typing by massively parallel pyrosequencing for high-resolution allele identification. Hum. Immunol. 2009, 70:960-964.
38. Gao F., Bailes E., Robertson D.L., Chen Y., Rodenburg C.M., Michael S.F., Cummins L.B., Arthur L.O., Peeters M., Shaw G.M., Sharp P.M., Hahn B.H. Origin of HIV-1 in the chimpanzee Pan trogolodytes trogolodytes. Nature 1999, 397:436-441.
39. Gao X., Nelson G.W., Karacki P., Martin M.P., Phair J., Kaslow R., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., O'Brien S.J., Carrington M. Effect of a single amino acid change in MHC class I molecules on the rate of progression of AIDS. N. Engl. J. Med. 2001, 344:1668-1675.
40. Gao X., Bashirova A., Iversen A.K., Phair J., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Altfeld M., O'Brien S.J., Carrington M. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat. Med. 2005, 11:1290-1292.
41. Gaudieri S., DeSantis D., McKinnon E., Moore C., Nolan D., Witt C.S., Mallal S.A., Christiansen F.T. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun. 2005, 2005(6):683-690.
42. Gesprasert G., Wichukchinda N., Mori M., Shiino T., Auwanit W., Sriwanthana B., Pathipvanich P., Sawanpanyalert P., Miura T., Auewarakul P., Thitithanyanont A., Ariyoshi K. HLA-associated immune pressure on Gag protein in CRF01_AE-infected individuals and its association with plasma viral load. PLoS ONE 2010, 5(6):e11179.
43. Guerini F.R., Lo Caputo S., Gori A., Bandera A., Mazzotta F., Uglietti A., Zanzottera M., Maserati R., Clerici M. Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals. J. Infect. Dis. 2011, 203:1235-1239.
44. Hansasuta P., Dong T., Thananchai H., Weckes M., Willberg C., Aledemir H., Rowland-Jones S., Braud V.M. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 2004, 34:1673-1679.
45. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20:W13-W23.
46. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689. WHO-UNAIDS network for HIV isolation and characterisation.
47. Hempel U., Buranapraditkun S., Chatkulkawin P., Pitakpolrat P., Phillips L.C., Allgaier R.L., Lorenzen S., Hildebrand W.H., Leitner T., Matthews P., Goulder P., Walker B.D., Ruxrungtham K., Allen T.M. P16-07. HLA-B1302 is associated with viral control in clade CRF01_AE HIV-1 infection in Thailand. Retrovirology 2009, 6(Suppl. 3):236.
48. Hendel H., Caillat-Zucman S., Lebuanec H., Carrington M., O'Brien S., Andrieu J.-M., Schachter F., Zagury D., Rappaport J., Winkler C., Nelson G.W., Zagury J.-F. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol. 1999, 162:6942-6946.
49. Hertz T., Nolan D., James I., John M., Gaudieri S., Phillips E., Huang J.C., Riadi G., Mallal S., Jojic N. Mapping the landscape of host-pathogen evolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J. Virol. 2011, 85:1310-1321.
50. Hiby S.E., Walker J.J., O'Shaughnessy K.M., Redman C.W.G., Carrington M., Trowsdale J., Moffett A. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 2004, 200:957-965.
51. Honeyborne I., Prendergast A., Pereyra F., Leslie A., Crawford H., Payne R., Reddy S., Bishop K., Moodley E., Nair K., van der Stok M., McCarthy N., Rousseau C.M., Addo M., Mullins J.I., Brander C., Kiepiela P., Walker B.D., Goulder P.J. Control of human immunodeficiency virus type 1 is associated with HLA-B13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J. Virol. 2007, 81:3667-3672.
52. Horton R., Wilming L., Rand V., Lovering R.C., Bruford E.A., Khodiyar V.K., Lush M.J., Povey S., Talbot C.C., Wright M.W., Wain H.M., Trowsdale J., Ziegler A., Beck S. Gene map of the extended human MHC. Nat. Rev. Immunol. 2004, 5:889-899.
53. Huang X., Ling H., Feng L., Ding X., Zhou Q., Han M., Xiong H. Human leukocyte antigen proifile in HIV-1 infected individuals and AIDS patients from Chongqing. Chin. Microbiol. Immunol. 2009, 53:512-523.
54. John M., Heckerman D., James I., Park L.P., Carlson J.M., Chopra A., Gaudieri S., Nolan D., Hass D.W., Riddler S.A., Haubrich R., Mallal S. Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J. Immunol. 2010, 184:4368-4377.
55. Kaslow R.A., Carrington M., Apple R., Park L., Munoz A., Saah A.J., Goedert J.J., Winkler C., O'Brien S.J., Rinaldo C., Detels R., Blattner W., Phair J., Erlich H., Mann D.L. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 1996, 2:405-411.
56. Kawashima Y., Pfafferott K., Fratyer J., Mathews P., Payne P., Addo M., Gatanaga H.K., Fujiwara M., Hachiya A., Koizumi H., Kuse N., Oka S., Duda A., Prendergast A., Crawford H., Leslie A., Brumme Z., Brumme C., Allen T., Brander C., Kaslow R., Tang J., Hunter E., Allen S., Mulenga J., Branch S., Roach T., John M., Mallal S., Ogwu A., Shapiro R., Prado J.g., Fidler S., Weber J., Pybus O.G., Klenerman P., Ndung'u T., Phillips R., Heckerman D., Harrigan P.R., Walker P.R., Walker P.R., Takiguchi M., Goulder P. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009, 458:641-646.
57. Keet I.P., Tang J., Klein M.R., LeBlanc S., Enger C., Rivers C., Apple R.J., Mann D., Goedert J.J., Miedema F., Kaslow R.A. Consistent associations of HLA class I and II and transporter gene products with progression of HIV-1 infection in homosexual men. J. Infect. Dis. 1999, 180:299-309.
58. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., Rathnavalu P., Moore C., Pjafferott K.J., Hilton L., Zimbwa P., Moore S., Allen T., Brander C., Addo M.M., Altfield M., James I., Mallal S., Bunce M., Barber L.D., Szinger J., Day C., Klenerman P., Mullins J., Korber B., Coovadia H.M., Walker B.D., Goulder P.J.R. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004, 432:769-774.
59. Kim J.H., Rerks-Ngarm S., Excler J.L., Michael N.L. HIV vaccines: lessons learned and the way forward. Curr. Opin. HIV AIDS 2010, 5:428-434.
60. Koehler R.N., Walsh A.M., Saathoff E., Tovenabutra S., Arroyo M.A., Currier J.R., Maboko L., Hoelsher M., Robb M.L., Michael N.L., McCutchan F.E., Kim J.H., Kijak G.H. Class I HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya. Tanzania J. Infect. Dis. 2010, 202:1562-1566.
61. Kollinberger S., Bird L., Sun M.Y., Retiere C., Braud V.M., McMichael A., Bowness P. Cell surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum. 2002, 46:2972-2982.
62. Kulkarni S., Savan R., Qi Y., Gao X., Yuki Y., Bass S.E., Martin M.P., Hunt P., Deeks S.G., Telenti A., Pereyra F., Goldstein D., Wolinsky S., Walker B., Young H.A., Carrington M. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011, 472:495-498.
63. Kuniholm M.H., Gao X., Xue X., Kovacs A., Anastos K., Marti D., Greenblatt R.M., Cohen M.H., Minkoff H., Gange S.J., Fazzari M., Young M.A., Strickler H.D., Carrington M. Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy. J. Virol. 2011, 85:10826-10833.
64. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 2005, 23:225-274.
65. Lazaryan A., Lobashevsky E., Mulenga J., Karita E., Allen S., Tang J., Kaslow R.A. Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native Africans. J. Virol. 2006, 80:6056-6060.
66. Lazaryan A., Song W., Lobashevsky E., Tang J., Shrestha A., Mulenga J., Zhang K., Gardner L.J., McNicholl J.M., Wilson C.M., Klein R.S., Rompalao A., Mayer K., Sobel J., Kaslow R.A. Human leukocyte antigen class I supertypes and HIV-1 control in African Americans. J. Virol. 2010, 84:2610-2617.
67. Lazaryan A., Song W., Lobashevsky E., Tang J., Shrestha A., Mulenga J., Zhang K., McNicholl J.M., Gardner L.J., Wilson C.M., Klein R.S., Rompalo A., Mayer K., Sobel J., Kaslow R.A. The influence of human leukocyte antigen class I alleles and their population frequencies on human immunodeficiency virus type 1 control among African Americans. Hum. Immunol. 2011, 72:312-318.
68. Leslie A.J., Pfafferott K.J., Chetty P., Draenert R., Addo M.M., Feeney M., Tang Y., Holmes E.C., Allen T., Prado J.G., Altfield M., Brander C., Dixon C., Ramduth D., Jeena P., Thomas S.A., St John A., Roach T.A., Kupfer B., Luzzi G., Edwards A., Taylor G., Lyall H., Tudor-Williams G., Novelli V., Martinez-Picado J., Kiepiela P., Walker B.D., Goulder P.J. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 2004, 10:282-289.
69. Leslie A., Matthews P.C., Listgarten J., Carlson J.M., Kadie C., Ndung'u T., Brander C., Coovadia H., Walker B.D., Heckerman D., Goulder P.J. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J. Virol. 2010, 84:9879-9888.
70. Li S., Jiao H., Yu X., Strong A.J., Shao Y., Sun Y., Altfeld M., Lu Y. Human leukocyte antignen class I and II allele frequencies in a Chinese cohort. J. Acquir. Immune Defic. Syndr. 2007, 44:121-131.
71. Limou S., Le Clerc S., Coulonges C., Carpentier W., Dina C., Delaneau O., Labib T., Taing L., Sladek, ANRS Genomic Group, Deveau C., Ratsimandresy R., Montes M., Spandoni J.-L., Lelievre J.-D., Levy Y., Therwath A., Schachter F., Matsuda F., Gut I., Froguel P., Delfraissy J.-F., Hercberg S., Zagury J.-F. Genomic association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS genomewide association study 02). J. Inf. Dis. 2009, 199:419-426.
72. Liu C., Carrington M., Kaslow R.A., Gao X., Rinaldo C.R., Jacobson L.P., Margolick J.B., Phair J., O'Brien S.J., Detels R. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 2003, 187:1404-1410.
73. Lund O., Nielsen M., Kesmir C., Petersen A.G., Lundegaard C., Worning P., Sylvester-Hvid C., Lamberth K., Roder G., Justesen S., Buus S., Brunak S. Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 2004, 55:797-810.
74. MacDonald K.S., Fowke K.R., Kimani J., Dunand V.A., Nagelkerke N.J.D., Ball T.B., Oyugi J., Njagi E., Gaur L.K., Brunham R.C., Wade J., Luscher M.A., Krausa P., Rowland-Jones S., Ngugi E., Bwayo J.J., Plummer F.A. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 2000, 181:1581-1589.
75. MacDonald K.S., Embree J.E., Nagelkerke N.J.D., Castillo J., Ramhadin S., Njenga S., Oyug J., Ndinya-Achola J., Barber B.H., Bwayo J.J., Plummer F.A. The HLA A2/6802 supertype is associated with reduced risk of perinatal HIV-1 transmission. J. Infect. Dis. 2001, 183:503-506.
76. Marsh S.G.E., Albert E.D., Bodmer W.F., Bontrop R.E., Dupont B., Erlich H.A., Fernández-Viña M., Geraghty D.E., Holdsworth R., Hurley C.K., Lau M., Lee K.W., Mach B., Maiers M., Mayr W.R., Müller C.R., Parham P., Petersdorf E.W., Sasazuki T., Strominger J.L., Svejgaard A., Terasaki P.I., Tiercy J.M., Trowsdale J. Nomenclature for factors of the HLA system. Tissue Antigens 2010, 75:291-455.
77. Martin M.P., Carrington M. KIR locus polymorphisms: genotyping and disease association analysis. Methods Mol. Biol. 2008, 415:49-64.
78. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Trowsdale J., Wilson M., O'Brien S.J., Carrington M. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 2002, 31:429-434.
79. Martin M.P., Qi Y., Gao X., Yamada E., Martin J.N., Pereyra F., Colombo S., Brown E.E., Shupert W.L., Phair J., Goedert J.J., Buchbinder S., Kirk G.D., Telenti A., Connors M., O'Brien S.J., Walker B.D., Parham P., Deeks S.G., McVicar D.W., Carrington M. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 2007, 39:733-740.
80. Matthews P.C., Leslie A.J., Katzourakis A., Crawford H., Payne R., Prendergast A., Power K., Kelleher A.D., Klenerman P., Carlson J., Heckerman D., Ndung'u T., Walker B.D., Allen T.M., Pybus O.G., Goulder P.J. HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering. J. Virol. 2009, 83:4605-4615.
81. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., Buchbinder S.P., Robertson M.N., Mehrotra D.V., Self S.G., Corey L., Shiver J.W., Casimiro D.R. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905. Step Study Protocol Team.
82. Merino A., Malhotra R., Morton M., Mulenga J., Allen S., Hunter E., Tang J., Kaslow R.A. Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples. J. Infect. Dis. 2011, 203:487-495.
83. Moore C.B., John M., James I.R., Christiansen F.T., Witt C., Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296:1439-1443.
84. Nguyen L., Chaowanachan T., Vanichseni S., McNicholl J.M., Mock P.A., Nelson R., Hodge T.W., van Griensven F., Choopanya K., Mastro T.D., Tappero J.W., Hu D.J. Frequent human leukocyte antigen class I alleles are associated with higher viral load among HIV type 1 seroconverters. J. Acquir. Immune Defic. Syndr. 2004, 37:1318-1323.
85. Norman P.J., Stephens H.A.F., Verity D.H., Chandanayingyong D., Vaughan R.W. Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics 2001, 52:195-205.
86. Norman P.J., Cook M.A., Carey B.S., Carrington C.V.F., Verity D.H., Hameed K., Ramdath R.D., Chandanayingyong D., Leppert M., Stephens H.A.F., Vaughan R.W. SNP haplotypes and allele frequencies show evidence for disruptive and balancing selection in the human leukocyte receptor complex. Immunogenetics 2004, 56:225-237.
87. Norman P.J., Abi-Rached L., Gendzekhadze K., Korbel D., Gleimer M., Rowley D., Bruno D., Carrington C.V.F., Chandanayingyong D., Chang Y.-H., Crespi C., Saruhan-Direskeneli G., Fraser P., Hameed K., Kamkamidze G., Koram K.A., Layrisse Z., Matamoros N., Mila J., Park M.H., Pitchappan R.M., Ramdath D.D., Shiau M.-Y., Stephens H.A.F., Struik S., Verity D.H., Vaughan R.W., Tyan D., Davis R.W., Riley E.M., Ronaghi M., Parham P. Unusual selection on the KIR3DL1/S1 natural killer receptor in Africans. Nat. Genet. 2007, 39:1092-1099.
88. Norman P.J., Abi-Rached L., Gendzekhadze K., Hammond J.A., Moesta A.K., Sharma D., Graef T., McQueen K.L., Guethlein L.A., Carrington C.V.F., Chandanayinyong D., Chang Y.-H., Crespi C., Saruhan-Direskeneli G., Hameed K., Kamkamidze G., Koram K.A., Layrisse Z., Matamoros N., Mila J., Park M.L., Pitchappan R.M., Ramduth D.D., Shiau M.-Y., Stephens H.A.F., Struik S., Tyan D., Verity D.H., Vaughan R.W., Davis R.W., Fraser P.A., Riley E.M., Ronaghi M., Parham P. Meiotic recombination generates rich diversity in NK receptor genes, alleles and haplotypes. Genome Res. 2009, 19:757-769.
89. Nussbaum A.K., Kuttler C., Tenzer S., Hansjorg S. Using the world wide web for predicting CTL epitopes. Curr. Opin. Immunol. 2003, 15:69-74.
90. O'Brien S.J., Gao X., Carrington M. HLA and AIDS: a cautionary tale. Trends Mol. Med. 2001, 7:379-381.
91. Pando M.J., Gardiner C.M., Gleimer M., McQueen K.L., Parham P. The protein made from a common allele of KIR3DL1 (3DL1004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J. Immunol. 2003, 171:6640-6649.
92. Parham P. Immunogenetics. Soaring costs in defence. Nature 1999, 401:870-871.
93. Parham P. NK cells and trophoblasts: partners in pregnancy. J. Exp. Med. 2004, 200:951-955.
94. Parham P. MHC class I molecules and KIRS in human history, health and survival. Nat. Rev. Immunol. 2005, 9:201-214.
95. Parham P., Ohta T. Population biology of antigen presentation by MHC class I molecules. Science 1996, 272:67-74.
96. Paris R., Bejrachandra S., Karnasuta C., Chandanayingyong D., Kunachiwa W., Leetrakool N., Prakalapakorn S., Thongcharoen P., Nittayaphan S., Pitisuttithum P., Suriyanon V., Gurunathan S., McNeil J.G., Brown A.E., Birx D.L., de Souza M. HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. Tissue Antigens 2004, 64:251-256.
97. Paris R., Bejrachandra S., Thongcharoen P., Nitayaphan S., Pitisuttithum P., Sambor A., Gurunathan S., Francis D., Ratto-Kim S., Karnasuta C., de Souza M.S., Polonis V.R., Brown A.E., Kim J.H., Stephens H.A. HLA class II restriction of HIV-1 clade-specific neutralising antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX® B/E. Vaccine 2012, 30:832-836.
98. Pascal V., Yamada E., Martin M.P., Alter G., Altfeld M., Metcalf J.A., Baseler M.W., Adelsberger J.W., Carrington M., Anderson S.K., McVicar D.W. Detection of KIR3DS1 on the cell surface of peripheral blood NK cells facilitates identification of a novel null allele and assessment of KIR3DS1 expression during HIV-1 infection. J. Immunol. 2007, 179:1625-1633.
99. Pelak K., Goldstein D.B., Walley N.M., Fellay J., Ge D., Shianna K.V., Gumbs C., Gao X., Maia J.M., Cronin K.D., Hussain S.K., Carrington M., Michael N.L., Weintrob A.C. Host determinants of HIV-1 control in African Americans. J. Infect. Dis. 2009, 201:1141-1149.
100. Pelak K., Need A.C., Fellay J., Shianna K.V., Feng S., Urban T.J., Ge D., De Luca A., Martinez-Picado J., Wolinsky S.M., Martinson J.J., Jamieson B.D., Bream J.H., Martin M.P., Borrow P., Letvin N.L., McMichael A.J., Haynes B.F., Telenti A., Carrington M., Goldstein D.B., Alter G. Copy number variation of KIR genes influences HIV-1 control. PLoS 2011, 11(9):e1001208. NIAID Center for HIV/AIDS Vaccine Immunology.
101. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., Hu D., Tappero J.W., Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194:1661-1671. Bangkok Vaccine Evaluation Group.
102. Prugnolle F., Manica A., Charpentier M., Guegan J.F., Guernier V., Balloux F. Pathogen-driven selection of worldwide HLA class I diversity. Curr. Biol. 2005, 15:1022-1027.
103. Qi Y., Martin M.P., Gao X., Jacobson L., Goedert J.J., Buchbinder S., Kirk G.D., O'Brien S.J., Trowsdale J., Carrington M. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2006, 2(8):e79.
104. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
105. Robinson J., Mistry K., McWilliam H., Lopez R., Marsh S.G. IPD - the Immuno Polymorphism Database. Nucleic Acids Res. 2010, 38:D863-D869.
106. Saathoff E., Pritsch M., Geldmacher C., Koehler R.N., Maboko L., Maganga L., Geis S., McCutchan F., Kijak G.H., Kim J.H., Arroyo M.A., Gerhardt M., Tovanabutra S., Robb M.L., Williamson C., Michael N.L., Hoelscher M. Viral and host factors associated with the HIV-1 viral load setpoint in adults form Mbeya region. Tanzania J. Acquir. Immune Defic. Syndr. 2010, 54:324-330.
107. Sathiamurthy M., Hickman H.D., Cavett J.W., Zahoor A., Prilliman K., Metcalf S., Fernandez Vina M.A., Hildebrand W.H. Population of the HLA ligand database. Tissue Antigens 2003, 61:12-19.
108. Sette A., Sidney J., Livingston B.D., Dzuris J.L., Crimi C., Walker C.M., Southwood S., Collins E.J., Hughes A.I. Class I molecules with similar peptide-binding specificities are the result of both common ancestry and convergent evolution. Immunogenetics 2003, 54:830-841.
109. Sidney P., Peters B., Frahm N., Brander C., Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 2008, 9:1-15.
110. Sriwanthana B., Hodge T., Mastro T.D., Dezzutti C.S., Bond K., Stephens H.A.F., Kostrikis L.G., Limpakarnjanarat K., Young N.L., Qari S.H., Lala R.B., Chanadanayingyong D., McNicholl J.M. HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine related factors may act synergistically to determine HIV resistance in CCR5 delta-32 negative female sex workers in Chiang Rai, northern Thailand. AIDS Res. Hum. Retroviruses 2001, 17:719-734.
111. Stephens H.A.F. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol. 2005, 26:41-47.
112. Sylvester-Hvid C., Nielsen M., Lamberth K., Justensen S., Lundegaard C., Worning P., Thomadsen H., Lund O., Brunak S., Buus S. SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation. Tissue Antigens 2004, 63:395-400.
113. Tang J., Costello C., Keet I.P.M., Rivers C., Leblanc S., Karita E., Allen S., Kaslow R.A. HLA class I homozygosity accelerates disease progression in HIV-1 infection. AIDS Res. Hum. Retroviruses 1999, 15:317-324.
114. Tang J., Tang S., Lobashevsky E.S., Myracle A.D., Fideli U., Aldrovandi G., Allen S., Musonda R., Kaslow R.A. Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. J. Virol. 2002, 76:8276-8284.
115. Tang J., Malhotra R., Song W., Brill I., Hu L., Farmer P.K., Mulenga J., Allen S., Hunter E., Kaslow R.A. Human leukocyte antigens and HIV type 1 load in early and chronic infection: predominance of evolving relationships. PLoS ONE 2010, 5(3):e9629.
116. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330:1551-1557. The International HIV Controllers Study.
117. Complete sequence and gene map of a human major histocompatibility complex. Nature 1999, 401:921-923. The MHC sequencing consortium.
118. Thomas R., Apps R., Qi Y., Gao X., Male V., O'hUigin C., O'Connor G., Ge D., Fellay J., Martin J.M., Margolick J., Goedert J.J., Buchbinder S., Kirk G.D., Martin M.P., Telenti A., Deeks S.G., Walker B.D., Goldstein D., McVicar D.W., Moffett A., Carrington M. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat. Genet. 2009, 12:1290-1294.
119. Tibayrenc M. Human genetic diversity and the epidemiology of parasitic diseases and other transmissible diseases. Adv. Parasitol. 2007, 64:377-428.
120. Trachtenberg E., Korber B., Sollars C., Kepler T.B., Hraber P.T., Hayes E., Funkhouser R., Fugate M., Theiler J., Hsu Y.S., Kunstman K., Wu S., Phair J., Erlich H., Wolinsky S. Advantage of a rare HLA supertype in HIV disease progression. Nat. Med. 2003, 9:928-935.
121. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 1989, 47:187-376.
122. Ugloni S., Vivier E. Multifaceted roles of MHC class I and MHC class I-like molecules in T cell activation. Nat. Immunol. 2001, 2:198-200.
123. Uhberg M., Valiante N.M., Shum B.P., Shilling H.G., Lienert-Weidenbach K., Corliss B., Tyan D., Lanier L.L., Parham P. Human diversity in killer cell inhibitory receptor genes. Immunity 1997, 7:753-763.
124. Van Manen D., Kootstra N.A., Boeser-Nunnink B., Handulle M.A., van't Wout A.B., Schuitemaker H. Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 2009, 23:19-28.
125. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008, 9:503-510.
126. Wong A.H., Williams K., Reddy S., Wilson D., Giddy J., Alter G., Ghebremichael M., Carrington M.N., Ndung'u T., Walker B.D., Altfeld M., Carr W.H. Alterations in natural killer cell receptor profiles during HIV type 1 disease progression among chronically infected South African adults. AIDS Res. Hum. Retroviruses 2010, 26:459-469.
127. Yoon W., Ma B.J., Fellay J., Huang W., Xia S.M., Zhang R., Shianna K.V., Liao H.X., Haynes B.F., Goldstein D.B. A polymorphism in the HCP5 gene associated with HLA-B5701 does not restrict HIV-1 in vitro. AIDS 2010, 24:155-157. NIAID Center for HIV/AIDS Vaccine Immunology.
128. Zinkernagel R.M., Doherty P.C. The discovery of MHC restriction. Immunol. Today 1997, 18:14-17.